Trials / Terminated
TerminatedNCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
Conditions
- GVHD (Acute or Chronic)
- Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
- Myelodysplastic Syndrome
- Chronic Myelogenous Leukemia (CML)
- Multiple Myeloma (MM)
- Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
- Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | milatuzumab | Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously. |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2012-08-13
- Last updated
- 2021-08-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01663766. Inclusion in this directory is not an endorsement.